The Day In Review: Bioenvision Wins European Approval For Evoltra

June 1, 2006 -- Bioenvision won European approval for Evoltra as a therapy for leukemia patients who failed two earlier treatments; Cell Therapeutics said the FDA agreed to a shorter approval plan for lung cancer drug Xyotax; OSI Pharma reported positive interim results for Macugen, its anti-angiogenesis drug for blindness; CombinatoRx received up to $13.8 million in research funds to investigate cystic fibrosis drugs; Vical said its vaccine for West Nile Virus passed its safety test; Isis Pharma received orphan drug status for a genetic disorder drug; Tanox said its entry inhibiting drug was effective against HIV in a laboratory study; ViroPharma filed to slow down approval for generic alternatives to Vancocin; and Schering-Plough will reduce its manufacturing workforce by 1,100 people. The Centient Biotech 200™ gained 45 points to end the session at 3739.91, a rise of 1.22%. More details...